Skip to content

Investigate the effect of crocin in methamphetamine users

Investigate the effect of crocin on clinical symptoms, psychological symptoms and cognitive functions in methamphetamine users

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250221064794N1
Enrollment
80
Registered
2025-02-25
Start date
2025-04-05
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methamphetamine dependence. Other stimulant related disorders

Interventions

Intervention 1: Intervention group: In this group of patients (n=40) will be requested to take two crocin tablets daily for 8 weeks (each tablet contain 15 mg crocin). The crocin tablets will be produ

Sponsors

Kashan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 55 Years

Inclusion criteria

Inclusion criteria: Aged 25 to 55 Patients with addiction (Evaluated by the drug abuse section of the Structured Clinical Interview for DSM-IV) Complete informed consent Patients using methamphetamine and amphetamine (test positive for methamphetamine) Seeking for treatment

Exclusion criteria

Exclusion criteria: Unwillingness to cooperate Patients with psychiatric, psychotic, and bipolar disorders Suicide attempts Consumption of crocin, anti-inflammatory, and antioxidant supplements during the last 3 months Users of warfarin Having high blood pressure and thyroid disease Positive urine test for cannabis People who are allergic to the study supplement and report side effects from taking the medication during the study.

Design outcomes

Primary

MeasureTime frame
Withdrawal. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Amphetamine Withdrawal Questionnaire (AWQ).;Craving. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Desire for Drug Questionnaire (DDQ craving).

Secondary

MeasureTime frame
Cognitive function. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Cognitive abilities questionnaire (CAQ).;Mental health. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Depression Anxiety Stress Scales (DASS) questionnaire.;Sleep Quality. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Pittsburgh Sleep Quality Index (PSQI) questionnaire.;Sexual function. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: International Index of Erectile Function (IIEF) questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Ghaderi

Kashan University of Medical Sciences

gaderiam@yahoo.com+98 31 3457 4191

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026